# Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

> **NCT04890236** · EARLY_PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 4 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **BIOLOGICAL:** Tisagenlecleucel

## Key facts

- **NCT ID:** NCT04890236
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-13
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-09-04
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890236, "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04890236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*